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Abdominal obesity is associated with metabolic risk factors for coronary heart disease 
(CHD).  Although we previously found that using liposuction surgery to remove 
abdominal subcutaneous adipose tissue (SAT) did not result in metabolic benefits, it is 
possible that postoperative inflammation masked the beneficial effects.  Therefore, this 
study provides a long-term evaluation of a cohort of subjects from our original study.   
Body composition and metabolic risk factors for CHD, including oral glucose tolerance, 
insulin resistance, plasma lipid profile and blood pressure were evaluated in 7 obese 
(39±2 kg/m
2
) women before and at 10, 27 and 84-208 weeks after large-volume 
liposuction.  Liposuction surgery removed 9.4 ±1.8 kg of body fat (16%±2% of total fat 
mass; 6.1±1.4 kg decrease in body weight), primarily from abdominal SAT; body 
composition and weight remained the same from 10 through 84-208 weeks.  Metabolic 
endpoints (oral glucose tolerance, homeostasis model assessment of insulin resistance, 
blood pressure and plasma triglyceride, HDL-cholesterol, and LDL-cholesterol 
concentrations) obtained at 10 through 208 weeks were not different from baseline and 
did not change over time. These data demonstrate that removal of a large amount of 
abdominal SAT by using liposuction does not improve CHD metabolic risk factors 




 Abdominal obesity  is associated with metabolic risk factors for coronary heart 
disease (CHD), including insulin resistance, impaired oral glucose tolerance, 
dyslipidemia, and increased blood pressure (1).
  
Diet-induced fat loss is recommended for 
obese patients who have these cardiometabolic risk factors, because even moderate (e.g. 
10%) weight loss improves all risk factors simultaneously (1-3). Unfortunately, 
successful long-term weight management is difficult to achieve with lifestyle therapy 
alone,(4) which has stimulated considerable interest in developing new, safe and effective 
obesity treatment options. 
 We previously evaluated the potential use of liposuction surgery as a therapeutic 
tool for treating persons who have abdominal obesity (5). Our data demonstrated that 
removal of large amounts of abdominal subcutaneous adipose tissue (~10 kg) did not 
improve CHD risk factors or insulin sensitivity when subjects were evaluated ~10 weeks 
after the liposuction procedure was performed.  However, it was suggested that 
liposuction-induced adipose tissue inflammation could have obscured the detection of 
metabolic benefits in our subjects, and that a longer time is needed to allow post-
procedure inflammation to fully subside (6-9). 
 The purpose of the present study was to evaluate the hypothesis that large-volume 
liposuction has long-term beneficial effects on CHD risk that were missed at our 10-12 
week post-procedure evaluation.  Therefore, we conducted long-term longitudinal 
assessments of body composition and metabolic CHD risk in a subset of subjects who 







Seven of the 15 women (47%) who participated in an earlier study that evaluated 
the short-term effects (~10 weeks) of large-volume liposuction on cardiovascular disease 
risk factors (5) agreed to participate in this long-term follow-up evaluation.  All subjects 
in the original study had abdominal obesity and a waist circumference >100 cm.  Subjects 
completed a comprehensive medical evaluation, which included a history and physical 
examination and standard blood and urine tests. All subjects provided written informed 
consent before participating in this the study, which was approved by the Human Studies 
Committee and the General Clinical Research Center Advisory Committee (GCRC) of 




Baseline assessments before liposuction  
Subjects were admitted to the GCRC after they fasted overnight (12 h). A 2-h oral 
glucose tolerance test (OGTT) was performed. A catheter was placed into an antecubital 
hand vein, which was heated to 55
○
C by using a thermostatically controlled box, to 
obtain arterialized blood samples. After baseline blood samples were obtained (time=0) 
to determine plasma glucose, LDL-cholesterol, HDL-cholesterol and triglyceride 
concentrations, subjects ingested 75 g of glucose.  Blood samples were then taken at 30, 
60, 90 and 120 min after glucose ingestion to determine plasma glucose concentrations.   
Total body fat and fat-free mass (FFM) were determined by using dual-energy x-
ray absorptiometry (Delphi-W densitometer, Hologic, Waltham, MA). Abdominal 
subcutaneous adipose tissue (SAT) visceral adipose tissue (VAT) and thigh adipose 
tissue masses were quantified by using magnetic resonance imaging (Siemens, Iselin, NJ). 
Eight, 10 mm thick, slice images were obtained at, and proximal to, the L4-L5 
intervertebral space and the superior border of the medial condoyle of the tibia, and 
analyzed for subcutaneous and intra-compartmental (abdomen or muscle) adipose tissue 
content (10). 
 
Liposuction procedure  
 
 After all baseline evaluations were obtained, each subject underwent large-
volume tumescent liposuction.  Superficial and deep subcutaneous abdominal fat was 
primarily removed, but smaller amounts of fat were removed from the arms, flanks, hips 
and thighs, to achieve additional cosmetic benefits. An average of 18±2 L of Ringers 
Lactate plus epinephrine-infiltrated adipose tissue, containing ~10 kg of abdominal 
subcutaneous fat, was aspirated from each subject. 
 
Assessments after liposuction  
Subjects were instructed to resume their normal lifestyle after the initial recovery 
period and to weigh themselves weekly at home. Each subject was contacted via phone 
by one of the investigators at least once every week until week 27 after liposuction to 
reinforce the maintenance of their usual food intake and physical activity, and to maintain 
a stable body weight. Body composition analyses, blood tests and the OGTT performed 
before liposuction were repeated at weeks 10 and 27 after liposuction and at a final 





Plasma glucose concentrations were determined by using a glucose analyzer 
(Yellow Springs Instrument, Yellow Springs, OH). Plasma total cholesterol, HDL-
cholesterol, and triglycerides (TG) were determined enzymatically (Roche/Hitachi 747 
Analyzer, Roche Diagnostics Corporation, Indianapolis, IN) by using commercially 
available kits; LDL-cholesterol was calculated by using the Friedewald equation (11). 
 
Statistical analyses 
A one-way analysis of variance with repeated measures, followed by Tukey’s 
LSD post hoc testing where indicated, was used to compare body composition and 
glucose and lipid concentrations between baseline and after liposuction. A p-value ≤0.05 




Body weight and composition  
  Body composition analyses at 10 weeks after the liposuction procedure 
demonstrated that liposuction caused a 9.4 ±1.8 kg decrease in body fat (16% ± 2% of 
total fat mass), which resulted in decreases in body weight and body mass index (BMI), 
without a significant change in FFM (Table 1). In addition, abdominal SAT volume 
decreased by 23% ± 7% 10 weeks after liposuction, whereas VAT and thigh SAT 
volumes did not change.  No subsequent changes in body weight, BMI, or any 
component of body composition occurred at subsequent analyses performed at 27 weeks 
and between 84 and 208 weeks after liposuction.  
 
CHD risk factors  
At baseline, four subjects had normal oral glucose tolerance and three had type 2 
diabetes that was being treated with oral hypoglycemic agents only. Liposuction did not 
alter blood pressure, or plasma LDL-cholesterol, triglyceride, HDL-cholesterol, and 
fasting glucose concentrations throughout the duration of the study (Table 2). In addition, 
plasma glucose concentrations during the OGTT at 10, 27 and 84-208 weeks after 
liposuction were similar to values obtained before liposuction (Figure 1). 
 
Changes in medications 
 During 84 to 208-weeks of this study, treatment with medications that affect 
plasma glucose or lipoproteins was changed in some subjects as directed by their primary 
physician. Three subjects who had diabetes experienced changes in medications: one 
began treatment with glimepiride and glargine insulin; one began treatment with glargine 
insulin and concomitantly decreased pioglitazone from 45 mg to 30 mg/day; and one 
decreased glucovance treatment from t.i.d. to b.i.d. Two subjects started statin therapy 
(pravastatin and rosuvastatin), and one required an increased dose of pravastatin (40 to 
80mg).  Among subjects, who did not have diabetes, one started treatment with 
pravastatin and olmesartan. 
 DISCUSSION 
 In this study, we evaluated the long-term effect of removing large amounts of 
subcutaneous adipose tissue on body composition and CHD risk factors.  Our data 
demonstrate that even though more than a 10% reduction in total body fat mass (~7% 
reduction in body weight) was maintained for 1.5-4 years after liposuction, oral glucose 
tolerance, blood pressure, and plasma triglyceride, HDL-cholesterol and LDL-cholesterol 
concentrations did not change.  These long-term results are consistent with our findings 
obtained 10 wks after large-volume liposuction (5), and make it unlikely that persistent 
postsurgical inflammation masked the metabolic benefits of liposuction that we reported 
previously.  The data from the present study and our earlier study demonstrate that 
liposuction does not result in short-term or long-term improvement in most of the key 
metabolic risk factors for CHD.   
The absence of a metabolic therapeutic effect in our subjects is strikingly different 
than the outcome expected from similar or even smaller decreases in body fat induced by 
diet therapy.  Small long-term reductions in body weight (fat) improve glucose tolerance 
and the other metabolic CHD risk factors evaluated in the present study (2, 3, 12-14).  
Our results suggest that decreasing body fat by generating a negative energy balance, 
which decreases fat cell size, intra-abdominal fat and ectopic fat (e.g. intrahepatic and 
intramyocellular triglyceride content), is necessary to achieve the metabolic benefits of 
weight loss.  Surgical aspiration of fat can improve physical appearance and function, but 
not the CHD metabolic risk factors associated with obesity, even after a long-term 
reduction in body fat.  However, the results from our study cannot exclude the possibility 
that removing larger amounts of body fat or fat from different locations would have 
resulted in metabolic improvements.  
 Weight regain is common after diet-induced weight loss (15).  In contrast, our 
subjects maintained their body weight and body composition for years after liposuction-
induced fat and weight loss.  Several factors could have been responsible for weight and 
body fat maintenance in our study subjects.  First, obese subjects who lose weight by 
dieting experience a decrease in body mass of multiple tissues and an obligate decrease in 
energy expenditure (16, 17).  It is difficult for many people to sustain the lifestyle 
changes in energy intake and physical activity needed to prevent an increase in body size 
back toward their baseline.  Although we did not measure energy expenditure, it is 
unlikely that weight loss in our subjects had an important effect on energy metabolism 
because the loss in weight was completely due to aspiration of body fat, which has low 
energy requirements.  Therefore, our subjects did not need to change their lifestyle habits 
to either achieve or maintain their fat loss.  Second, removal of the large panniculus of 
subcutaneous abdominal fat in our subjects likely improved their ability to ambulate and 
be more physically active.  Third, our subjects experienced considerable cosmetic 
benefits after liposuction, which likely improved their self-esteem and reinforced their 
desire not to gain weight.  This observation raises the possibility that body image should 
be used as an incentive within the framework of behavioral therapy for obesity.  Fourth, it 
is possible that the subjects who failed to achieve long-term weight and fat loss refused to 
participate in the scheduled follow-up study visits.  Therefore, our study population 
would have been biased by only including those who had a successful weight outcome.   
 Liposuction surgery removes billions of adipocytes from selected adipose tissue 
depots, and disrupts the connective tissue framework that supports adipocytes and other 
adipose tissue cells. Therefore, it is possible that weight (fat) gain after liposuction could 
have adverse cosmetic and metabolic effects if newly formed triglycerides are unable to 
accumulate in the aspirated areas and are redirected to other sites. However, the effect of 
liposuction on fat distribution and metabolic outcomes after subsequent weight gain in 
humans is not clear.   Data from studies conducted in lipectomized animal models 
demonstrate that regeneration of the removed fat pad is rare, but compensatory fat 
accumulation at other sites commonly occurs (18).  Information obtained from case 
reports in patients is consistent with the findings in animals, and suggest that weight gain 
after liposuction results in an increase in subcutaneous fat in areas that were not aspirated, 
such the back and breasts  (19-21). In addition, it is possible that the removal of 
subcutaneous fat by liposuction will enhance ectopic fat deposition in other organs, such 
as the liver and skeletal muscle, which is associated with insulin resistance and 
inflammation (22, 23). Additional studies are needed to determine the long-term effects 
of large-volume liposuction in patients who gain weight.  
In summary, surgical aspiration of a large amount of abdominal SAT does not 
improve CHD metabolic risk factors associated with abdominal obesity, despite a long-
term reduction in body fat. The absence of a therapeutic effect suggests that losing weight 
by inducing a negative energy balance, not by decreasing adipose tissue mass alone, is 
needed to achieve the metabolic benefits of weight loss.  
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Table legend 
 
Table 1.  Body composition and metabolic characteristics of study participants before 





Figure 1.  Plasma glucose concentrations during a 2-hour oral glucose tolerance test 
obtained before (●) and 10 (∆), 27 ( ) and 84-208 (□) weeks after large volume 
liposuction.  Plasma glucose concentrations are absolute values above baseline (time 0). 
 
 
 
 
